HIV-associated neurocognitive disorder—pathogenesis and prospects for treatment

D Saylor, AM Dickens, N Sacktor, N Haughey… - Nature Reviews …, 2016 - nature.com
In the past two decades, several advancements have improved the care of HIV-infected
individuals. Most importantly, the development and deployment of combination antiretroviral …

Controversies in HIV-associated neurocognitive disorders

S Nightingale, A Winston, S Letendre… - The Lancet …, 2014 - thelancet.com
Cross-sectional studies show that around half of individuals infected with HIV-1 have some
degree of cognitive impairment despite the use of antiretroviral drugs. However, prevalence …

Efavirenz and the CNS: what we already know and questions that need to be answered

N Apostolova, HA Funes, A Blas-Garcia… - Journal of …, 2015 - academic.oup.com
The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs
in the multidrug regimens used to treat HIV infection, in accordance with its well …

Pharmaceuticals account for a significant proportion of the extractable organic fluorine in municipal wastewater treatment plant sludge

KM Spaan, F Seilitz, MM Plassmann… - … & Technology Letters, 2023 - ACS Publications
Fluorine mass balance studies have shown that monomeric per-and polyfluoroalkyl
substances (PFAS) with perfluoroalkyl chain lengths of∼ 5–14 carbon atoms …

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

KR Mollan, M Smurzynski, JJ Eron, ES Daar… - Annals of internal …, 2014 - acpjournals.org
This article has been corrected. The original version (PDF) is appended to this article as a
Supplement. Background: The relationship between efavirenz use and suicidality is not well …

Neurological and psychiatric adverse effects of antiretroviral drugs

MS Abers, WX Shandera, JS Kass - CNS drugs, 2014 - Springer
Antiretroviral drugs are associated with a variety of adverse effects on the central and
peripheral nervous systems. The frequency and severity of neuropsychiatric adverse events …

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

Q Ma, F Vaida, J Wong, CA Sanders, Y Kao… - Journal of …, 2016 - Springer
Neurocognitive (NC) complications continue to afflict a substantial proportion of HIV-infected
people taking effective antiretroviral therapy (ART). One contributing mechanism for this is …

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled …

ENCORE1 Study Group - The Lancet, 2014 - Elsevier
Background The optimum dose of key antiretroviral drugs is often overlooked during product
development. The ENCORE1 study compared the efficacy and safety of reduced dose …

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?

J Underwood, KR Robertson, A Winston - Aids, 2015 - journals.lww.com
Whilst effective antiretroviral therapy is protective against the more severe forms of HIV-
associated brain disease, there remains a large burden of clinically symptomatic cognitive …

Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation

MM Parvez, A Basit, PB Jariwala, Z Gáborik… - Drug Metabolism and …, 2021 - ASPET
The anticancer drug irinotecan shows serious dose-limiting gastrointestinal toxicity
regardless of intravenous dosing. Although enzymes and transporters involved in irinotecan …